Evidence map›Paper›PMID 36678636›Full record

ArticlePharmaceutics2022

Combination of a Chaperone Synthesis Inducer and an Inhibitor of GAPDH Aggregation for Rehabilitation after Traumatic Brain Injury: A Pilot Study.

Elizaveta A Dutysheva, Elena R Mikhaylova, Maria A Trestsova, Alexander I Andreev, Danila Yu Apushkin, Irina A Utepova, Polina O Serebrennikova, Eugenia A Akhremenko, Nikolay D Aksenov, Elizaveta I Bon' and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Elizaveta A DutyshevaInstitute of Cytology of the Russian Academy of Sciences, 194064 St. Petersburg, Russia.
Elena R MikhaylovaInstitute of Cytology of the Russian Academy of Sciences, 194064 St. Petersburg, Russia.
Maria A TrestsovaDepartment of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Ekaterinburg, Russia.
Alexander I AndreevLaboratory of Experimental Pharmacology, Perm State University, 614990 Perm, Russia.
Danila Yu ApushkinLaboratory of Experimental Pharmacology, Perm State University, 614990 Perm, Russia.ORCID 0000-0003-4459-5264
Irina A UtepovaDepartment of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Ekaterinburg, Russia.
Polina O SerebrennikovaDepartment of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Ekaterinburg, Russia.
Eugenia A AkhremenkoLaboratory of Experimental Pharmacology, Perm State University, 614990 Perm, Russia.ORCID 0000-0003-0757-064X
Nikolay D AksenovInstitute of Cytology of the Russian Academy of Sciences, 194064 St. Petersburg, Russia.
Elizaveta I Bon'Department of Histology, Cytology and Embryology, Grodno State Medical University, 230009 Grodno, Belarus.
Sergey M ZimatkinDepartment of Histology, Cytology and Embryology, Grodno State Medical University, 230009 Grodno, Belarus.
Oleg N ChupakhinDepartment of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Ekaterinburg, Russia.
Boris A MargulisInstitute of Cytology of the Russian Academy of Sciences, 194064 St. Petersburg, Russia.
Irina V GuzhovaInstitute of Cytology of the Russian Academy of Sciences, 194064 St. Petersburg, Russia.ORCID 0000-0002-8775-7713
Vladimir F LazarevInstitute of Cytology of the Russian Academy of Sciences, 194064 St. Petersburg, Russia.
Institute of Cytology · RUUral Federal University · RUPerm State University · RUGrodno State Medical University · BY

Funding

Russian Science Foundation 18-74-10087Russian Science Foundation 22-13-00298
6 · The paper itself

Abstract

The recovery period after traumatic brain injury (TBI) is often complicated by secondary damage that may last for days or even months after trauma. Two proteins, Hsp70 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), were recently described as modulating post-traumatic processes, and in this study, we test them as targets for combination therapy using an inhibitor of GAPDH aggregation (derivative of hydrocortisone RX624) and an inducer of Hsp70 synthesis (the pyrrolylazine derivative PQ-29). The protective effect of the combination on C6 rat glioblastoma cells treated with the cerebrospinal fluid of traumatized animals resulted in an increase in the cell index and in a reduced level of apoptosis. Using a rat weight drop model of TBI, we found that the combined use of both drugs prevented memory impairment and motor deficits, as well as a reduction of neurons and accumulation of GAPDH aggregates in brain tissue. In conclusion, we developed and tested a new approach to the treatment of TBI based on influencing distinct molecular mechanisms in brain cells.

Indexed as

3-(5-phenyl-1H-pyrrol-2-yl)quinoxalin-2(1H)-oneGAPDHheat shock proteinHsp70hydrocortisone 21-hemisuccinaterehabilitation therapysecondary damagesmall moleculestraumatic brain injury

Identifiers

PMID36678636
PMCPMC9867013
OpenAlexW4313467156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.